{"gao_id": "GAO-18-292", "published": "2018-03-28T12:00:00Z", "released": "2018-03-28T08:00:00Z", "summary": "Mifeprex is a prescription drug used for the medical termination of early pregnancy. FDA approved changes to the indication and dosing regimen for the drug in 2016, including increasing the gestational age limit. Some are concerned with the safety of these changes and the effectiveness of FDA's monitoring. We found that FDA has not identified any significant concerns with the safety and use of Mifeprex...", "title": "Food and Drug Administration: Information on Mifeprex Labeling Changes and Ongoing Monitoring Efforts", "topics": ["Prescription drugs", "Physicians", "Patient care", "Safety", "Health Care", "Deaths", "Monitoring", "Women", "Drugs", "Reporting requirements", "Abortions", "Health care", "Adverse events", "Health care providers"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-18-292", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-18-292-highlights.pdf"}, {"title": "Full Report (34 pages)", "url": "https://www.gao.gov/assets/gao-18-292.pdf"}, {"title": "Accessible PDF (36 pages)", "url": "https://www.gao.gov/assets/700/691750.pdf"}]}